Watts Ryan J. 4
4 · Denali Therapeutics Inc. · Filed Feb 15, 2024
Insider Transaction Report
Form 4
Watts Ryan J.
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-02-13$17.29/sh−9,589$165,794→ 238,067 total
Holdings
- 2,242,604(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
- [F2]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price
- [F3]Includes 202,200 RSUs.
- [F4]Reflects 25,759 shares previously disclosed as held indirectly; but have been determined to be held directly.
- [F5]The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.